The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies

Author:

Shapira-Frommer Ronnie1,Niu Jiaxin2,Perets Ruth3,Peters Solange4,Shouse Geoffrey5ORCID,Lugowska Iwona6ORCID,Garassino Marina C.7,Sands Jacob8,Keenan Tanya9,Zhao Bin9,Healy Jane9,Ahn Myung-Ju10

Affiliation:

1. Division of Oncology and Clinical Research Institute at Rambam, Rambam Medical Center, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, 5265601, Israel

2. Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA

3. Clinical Research Institute at Rambam, Rambam Medical Center & Technion—Israel Institute of Technology, Haifa, 3109601,Israel

4. Vaud University Hospital Center, University of Lausanne, Lausanne,  1005, Switzerland

5. Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA

6. Early Phase Clinical Trials Unit, Maria Sklodowska Curie National Research Institute of Oncology, Warsaw,  00-001, Poland

7. The University of Chicago, Chicago, IL 60637, USA

8. Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA

9. Merck & Co., Inc., Rahway, NJ 07065, USA

10. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,  06351, Republic of Korea

Funder

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Publisher

Informa UK Limited

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3